Paris

• EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patients Recruiting
  2023-506282-66-00 5 2024-05-27 Women with ER+ HER2- metastatic breast cancer who progressed on first
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting
  2023-503219-14-01 10 2024-05-22 systemic sclerosis associated interstitial lung disease
• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo … Recruiting
  2023-506308-24-00 10 2024-05-22 Recurrent or metastatic head and neck squamous cell carcinoma
• A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CD … Recruiting
  2023-506888-34-00 1 2024-05-22 Advanced or metastatic solid tumors including hormone receptor positiv
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS- … Recruiting
  2023-505929-14-00 5 2024-05-21 Systemic Lupus Erythematosus
• An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evalu … Recruiting
  2023-508818-42-00 10 2024-05-21 Generalized Epidermolysis Bullosa Simplex (EBS)
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 Nervous system diseases
• A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants with Chronic Mye … Recruiting
  2023-507677-18-00 9 2024-05-17 Chronic Myeloid Leukemia
• Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy : A randomized phase III trial - COnCERTO (French 01-18) 20 … Recruiting
  2024-516456-17-00 5 2024-05-07 patients admitted for an obstructive colon cancer
• A study to extend treatment with JR-141 after completion of Study JR-141-GS31 Recruiting
  2022-503142-41-00 5 2024-05-06 Mucopolysaccharidosis type II
• Safety, Tolerability, PK, PD, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia Recruiting
  2023-505995-31-00 7 2024-05-03 Glanzmann Thrombasthenia
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom … Recruiting
  2023-507632-20-00 5 2024-05-01 Multiple Myeloma
• Phase 3 study to assess the efficacy and safety of Givinostat versus hydroxyurea in Polycythemia Vera patients Recruiting
  2022-502276-23-00 5 2024-04-25 JAK2V617F-positive high-risk Polycythemia Vera
• UVB: treatment of UVeitis in Behçet’s diseases with biologic Recruiting
  2024-513371-41-00 4 2024-04-25 Severe uveitis of Behçet’s disease
• Multi-cohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia TAILOR Recruiting
  2023-504044-34-00 4 2024-04-17 Untreated Chronic Lymphocytic Leukemia
• Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metas … Recruiting
  2023-506753-38-00 4 2024-04-16 metastatic gastric adenocarcinoma
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting
  2023-504865-21-00 5 2024-04-15 Essential Thrombocythemia patients who have an inadequate response to
• CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting
  2023-503317-29-00 5 2024-04-12 Metastatic renal cell carcinoma (mRCC)
• A randomised phase II placebo-controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus … Recruiting
  2024-516150-22-00 4 2024-04-11 HIV
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV … Recruiting
  2023-506232-32-00 9 2024-04-08 Multiple recurrences of Clostridioides difficile infection treated wit
• A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participa … Recruiting
  2023-503208-94-00 6 2024-04-04 Prostate cancer
• A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch … Recruiting
  2023-504899-25-00 5 2024-04-04 Metastatic castration resistant prostate cancer

Showing 961–984 of 2,286 trials